Table 2. Description of included trials using acceleration or hyperfractionation radiotherapy schedules in non-small cell lung cancer.
| Trial | No. patients randomised | Inclusion period | RT dose/no. of fractions | Dose per fraction | Duration (weeks) | Chemotherapy |
|---|---|---|---|---|---|---|
| Ball 1999 (23) | 204 | 1989-1995 | Control arm: 60 Gy/30 | 2 Gy OD | 6 | +/- concurrent |
| Experimental arm: 60 Gy/30 | 2 Gy BID | 3 | +/- concurrent | |||
| CHART (18,19) | 563 | 1990-1995 | Control arm: 60 Gy/30 | 2 Gy OD | 6 | None |
| Experimental arm: 54 Gy/36 | 1.5 Gy TID | 1.5 | None | |||
| Fu 1997 (22) | 69 | 1991-1994 | Control arm: 60-64 Gy/32-34 | 1.8-2.0 Gy OD | 7 | Adjuvant or none |
| Experimental arm: 74.3 Gy/66-69 | 1.1 Gy TID | 6.5 | Adjuvant or none | |||
| CHARTWEL-trial (ARO 97-1) (24) | 406 | 1997-2005 | Control arm: 66 Gy/33 | 2 Gy OD | 6.5 | Induction or none |
| Experimental arm: 60 Gy/40 | 1.5 Gy TID | 2.5 | Induction or none | |||
| ECOG 2597 (25) | 119 | 1998-2001 | Control arm: 64 Gy/32 | 2 Gy OD | 6.5 | Induction |
| Experimental arm: 57.6 Gy/36 | 1.6 Gy TID | 2.5 | Induction | |||
| Nyman 2009 (26) | 152 | 2002-2005 | Control arm: 60 Gy/30 | 2 Gy OD | 6 | Induction & concurrent |
| Control arm: 60 Gy/30 | 2 Gy OD | 6 | Induction & concurrent | |||
| Experimental arm: 64.6 Gy/38 | 1.7 Gy BID | 4.5 | Induction & concurrent | |||
| Van Baardwijk 2012 (27) | 137 | 2006-2009 | Total dose 51-69 Gy | Total 6-7 | Concurrent | |
| Study dose: phase 1 45 Gy/30 | 1.5 Gy BID | 3 | ||||
| Study dose: phase 2 isotoxic | 2 Gy OD for remainder | 3-4 |
Abbreviations: CHART, Continuous Hyperfractionated Accelerated Radiation Therapy; CHARTWEL, CHART Week-End Less; ECOG, Eastern Cooperative Oncology Group; No, Number; RT, Radiotherapy; OD, RT given once a day; RTOG, Radiation Therapy Oncology Group; BID, RT given twice a day; TID, RT given three times a day.